Pseudomyogenic Hemangioendothelioma

Author(s):  
Jason L. Hornick
2020 ◽  
Vol 83 (6) ◽  
pp. AB213
Author(s):  
Katherine Glaser ◽  
Brandon Beal ◽  
Melissa Piliang ◽  
Kathryn Riley

2016 ◽  
Vol 11 (1) ◽  
Author(s):  
Shintaro Sugita ◽  
Hiroshi Hirano ◽  
Noriaki Kikuchi ◽  
Terufumi Kubo ◽  
Hiroko Asanuma ◽  
...  

Biology ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1160
Author(s):  
Kasey J. McCollum ◽  
Rami N. Al-Rohil

Neoplasms of uncertain biological behavior present physicians with a genuine conundrum in practice. Cutaneous vascular neoplasms within this category are exceedingly rare, possessing significant gaps and uncertainty in many facets of clinical practice. Firstly, lesions were selected for review based on their categorization as indeterminate behavior, indicating the potential for local recurrence and rarely metastasize. After identification of the target lesions, a comprehensive review of the literature using national databases produced several landmark studies and case series regarding these neoplasms. Limiting the review to only cutaneous limited tumors narrowed the pool of studies; however, quite a large sum of papers remained. Examination of each paper yielded beneficial results on diagnosing, effective treatments, follow-up findings, and prognosis for each indeterminate lesion discussed. Overall, the literature search combined the molecular, histologic, immunohistochemical, surgical strategies to develop an up-to-date and comprehensive framework to guide physicians when encountering such lesions. The tumors reviewed include: kaposiform hemangioendothelioma, endovascular papillary angioendothelioma, pseudomyogenic hemangioendothelioma, retiform hemangioendothelioma, epithelioid hemangioendothelioma, and composite hemangioendothelioma.


2017 ◽  
pp. 328-333
Author(s):  
G. Petur Nielsen ◽  
Andrew E. Rosenberg ◽  
Vikram Deshpande ◽  
Francis J. Hornicek ◽  
Susan V. Kattapuram ◽  
...  

2020 ◽  
Vol 45 (5) ◽  
pp. 368-369
Author(s):  
Nicolas Plouznikoff ◽  
Stephanie A. Mourad ◽  
Sophie Turpin ◽  
Robert E. Turcotte ◽  
David A. Mitchell ◽  
...  

2019 ◽  
Vol 31 (5) ◽  
pp. 591
Author(s):  
Chao-Yu Liao ◽  
Chao-Kuei Juan ◽  
Chi-Shun Yang ◽  
Yi-Ju Chen

2019 ◽  
Vol 6 (7) ◽  
pp. C75-79
Author(s):  
Kumarguru B. N. Kumarguru B. N. ◽  
◽  
Navya N Navya N ◽  
Prashanth R Prashanth R ◽  
Arathi C. A. Arathi C. A. ◽  
...  

2021 ◽  
Author(s):  
Jun Ren ◽  
Xiaohui Wang ◽  
Yulin Zhou ◽  
Xin Yue ◽  
Shouhui Chen ◽  
...  

Pseudomyogenic hemangioendothelioma (PHE) is an extremely rare disease that affects mainly the young and more men than women. PHE are multicentric, locally aggressive, have low metastatic potential, and affect multiple tissue planes. Genetic aberrations are frequently detected in PHE and may play important roles in the occurrence, development, and treatment of this disease. In this study, we report a case of PHE with a novel SERPINE1-FOSB fusion gene. The fusion introduced a strong promoter near the coding region of FOSB, resulting in overexpression of intact FOSB. Immunohistochemical analysis showed overexpression of pAKT and mTOR in tumor cells, suggesting activation of the PI3K-AKT-mTOR signaling pathway. The patient responded well to targeted therapy with sirolimus, an mTOR inhibitor. Our study correlated dysregulation of a specific signaling pathway and the effectiveness of a targeted therapy to a specific genetic aberration. This information may be useful for future investigations of targeted therapeutics and provide a potential predictive biomarker for therapeutic effectiveness in cases of PHE with this genetic aberration.


Sign in / Sign up

Export Citation Format

Share Document